Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2013 | 06-2013 | 03-2013 | 12-2012 | 09-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -103,165 | -61,135 | -42,084 | -121,287 | -59,220 |
| Depreciation Amortization | 998 | 711 | 451 | 1,525 | 1,090 |
| Accounts receivable | -2,009 | 549 | -1,178 | -1,080 | -1,162 |
| Other Working Capital | 1,347 | 255 | -2,133 | -5,305 | -6,582 |
| Other Operating Activity | 55,956 | 32,625 | 29,951 | 96,453 | 43,338 |
| Operating Cash Flow | $-46,873 | $-26,995 | $-14,993 | $-29,694 | $-22,536 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,762 | -435 | -9 | -108 | -108 |
| Purchase Of Investment | -7,807 | -7,807 | -7,250 | N/A | N/A |
| Purchase Sale Intangibles | -1,281 | -931 | -461 | -1,037 | -614 |
| Other Investing Activity | -1,281 | -931 | -461 | -1,037 | -614 |
| Investing Cash Flow | $-10,850 | $-9,173 | $-7,720 | $-1,145 | $-722 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -67 | -45 | -22 | -85 | -64 |
| Common Stock Issued | 143,951 | 4,915 | 2,993 | 178,681 | 21,405 |
| Other Financing Activity | -178 | -178 | 0 | 0 | 0 |
| Financing Cash Flow | $143,706 | $4,692 | $2,971 | $178,596 | $21,341 |
| Beginning Cash Position | 187,661 | 187,661 | 187,661 | 39,904 | 39,904 |
| End Cash Position | 273,644 | 156,185 | 167,919 | 187,661 | 37,987 |
| Net Cash Flow | $85,983 | $-31,476 | $-19,742 | $147,757 | $-1,917 |
| Free Cash Flow | |||||
| Operating Cash Flow | -46,873 | -26,995 | -14,993 | -29,694 | -22,536 |
| Capital Expenditure | -1,762 | -435 | -9 | -108 | -108 |
| Free Cash Flow | -48,635 | -27,430 | -15,002 | -29,802 | -22,644 |